SCHEMBL1607149

SCHEMBL1607149

C[S+]([O-])CCCCCN=C=S

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 5/20 0.54
TRPA1 O75762 8/20 0.48
MIF P14174 4/20 0.48
GSK3B P49841 1/20 0.46
KEAP1 Q14145 2/20 0.42
NFE2L2 Q16236 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
BACH1 O14867 1/20 0.42
MAFK O60675 1/20 0.42
EGFR P00533 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1607282 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL5070755 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL1607124 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL14933784 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL14933787 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL25332541 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL1606718 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL106183 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
SCHEMBL2485837 1.00 NAAA (0.54) NAAATRPA1MIFGSK3BKEAP1
Sulforaphane SCHEMBL20855320 0.98 NAAA (0.50) NAAATRPA1MIFGSK3BKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250160275-A1 COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-05-22 US claimed
US-20250032470-A1 Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells WAYNE STATE UNIVERSITY (US) 2025-01-30 US claimed
WO-2023096511-A1 DRUG LIPID CARRIER, PHARMACEUTICAL FORMULATION, USES THEREOF AND METHOD FOR PREPARATION OF DRUG LIPID CARRIER, CARRIER OBTAINED BY THIS METHOD AND USES THEREOF UNIWERSYTET WARSZAWSKI (PL) 2023-06-01 WO claimed
EP-1313377-B1 TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES FAHEY JED W (US) 2015-01-21 EP claimed
EP-2163238-A2 Compound for lightening skin tone comprising sulforaphane or sulforaphene or their derivates Henkel AG & Co. KGaA (DE) 2010-03-17 EP claimed
US-20090326056-A1 NOVEL ACTIVES AGAINST PROSTATE CARCINOMA DSM IP ASSETS B.V. (NL) 2009-12-31 US claimed
EP-1569628-B1 NOVEL USE OF LYCOPENE FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ANDROGEN SIGNALLING DSM IP ASSETS BV (NL) 2009-07-22 EP claimed
EP-2020997-A2 NOVEL ACTIVES AGAINST PROSTATE CARCINOMA DSMIP Assets B.V. (NL) 2009-02-11 EP claimed
WO-2007131767-A2 NOVEL ACTIVES AGAINST PROSTATE CARCINOMA DSM IP ASSETS B.V. (NL) 2007-11-22 WO claimed
US-7232583-B2 Method for preparing isothiocyanate(s) from cruciferous plant material KINJIRUSHI CO., LTD. (JP) 2007-06-19 US claimed
EP-1476143-A1 COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES DSM IP Assets B.V. (NL) 2004-11-17 EP claimed
US-20040180843-A1 Treatment of helicobacter with isothocyanates BRASSICA FOUNDATION FOR CHEMOPROTECTION RESEARCH, INC. 2004-09-16 US claimed
WO-2004052351-A1 NOVEL USE OF LYCOPENE DSM IP ASSETS B.V. (CH) 2004-06-24 WO claimed
US-6737441-B2 PREVENTING OR TREATING PERSISTENT CHRONIC GASTRITIS, ULCERS AND/OR STOMACH CANCER Fahey, Jed W. 2004-05-18 US claimed
CN-1469711-A Treatment of helicobacter with isothiocyanates W 2004-01-21 CN claimed
WO-2003068202-A1 COMPOSITIONS COMPRISING LYCOPENE FOR THE TREATMENT AND PREVENTION OF ANGIOGENESIS ASSOCIATED PATHOLOGIES DSM IP ASSETS B.V. (NL) 2003-08-21 WO claimed
EP-1313377-A2 TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES Fahey, Jed W. (US) 2003-05-28 EP claimed
US-20030064131-A1 Method for preparing isothiocyanate(s) from cruciferous plant material JAPANESE R AND D ASSOC. FOR NEW FUNCTIONAL FOODS (JP) 2003-04-03 US claimed
US-20020151505-A1 Treatment of helicobacter with isothiocyanates FAHEY, JED W. 2002-10-17 US claimed
WO-2002015722-A2 TREATMENT OF HELICOBACTER WITH ISOTHIOCYANATES FAHEY JED W (US) 2002-02-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250032470-A1 Electrophilic Androgen Receptor (AR) Antagonists for AR Downregulation and Ferroptosis Induction in Cancer Cells AR, GSR, GPX1 NAAA 842/4885TRPA1 548/4885MIF 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.